Yinduo Zeng

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

Jieqiong Liu, Ying Wang, Zhenluan Tian et al. · Nature Communications · 2022 · 101 citations · Full text

Medicine, Oncology, Pharmacology +16

<scp>ARHGAP</scp>42 promotes cell migration and invasion involving <scp>PI</scp>3K/Akt signaling pathway in nasopharyngeal carcinoma

Qian Hu, Xiao Lin, Linxiaoxiao Ding et al. · Cancer Medicine · 2018 · 47 citations · Full text

Medicine, Molecular Biology, Oncology +17

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system

Xiujuan Gui, Jianli Zhao, Linxiaoxiao Ding et al. · Frontiers in Oncology · 2023 · 13 citations · Full text

Pharmacy, Pharmacology, Clinical Pharmacology +16

Targeting autophagy plus high-dose CDK4/6 inhibitors in advanced HR+HER2− breast cancer: A phase 1b/2 trial

Chang Gong, Qun Lin, Tao Qin et al. · Med · 2024 · 13 citations · Full text

Medicine, Cancer Biology, Oncology +16

Detection and Analysis of Living, Growth-Inhibited Mammalian Cells Following Transfection

Yinduo Zeng, Kumaravel Somasundaram, N S Prabhu et al. · BioTechniques · 1997 · 12 citations · Full text

Life Sciences, Cell Biology, Cell Proliferation +9